Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.42 |
| ▸ | CTSL | P07711 | 4/20 | 0.42 |
| ▸ | CTSB | P07858 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 5/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2681100 | 0.98 | CTSK (0.43) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL1503616 | 0.86 | CTSK (0.45) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL1504589 | 0.83 | CA1 (0.41) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL18857996 | 0.83 | CTSK (0.41) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL1504675 | 0.82 | PREP (0.37) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL29286947 | 0.80 | CTSK (0.47) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL8624859 | 0.78 | CTSK (0.48) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL10592724 | 0.78 | CTSK (0.48) | CTSKCTSLCTSBCA1CA2 | |
| SCHEMBL1504753 | 0.77 | POLB (0.47) | CTSLCYP2D6KMT2AMEN1TSHR | |
| Cyclopentane SCHEMBL28225777 | 0.74 | KMT2A (0.48) | CTSKCTSLCTSBCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772478-B2 | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-07-08 | — | — | US | disclosed |
| US-20120116072-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | GALDERMA RESEARCH & DEVELOPEMENT (FR) | 2012-05-10 | — | — | US | disclosed |
| WO-2011033010-A1 | 4-ALKOXY-N- (2-HYDROXYCARBAMOYL-2-PIPERIDINYL-ETHYL) -BENZAMIDE COMPOUNDS AS SELECTIVE TACE-INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116072-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | TYR, ARSA, STS | CTSK 956/4885CTSL 3659/4885CTSB 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.